Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals |
| gptkbp:activities |
dopamine D2 receptor antagonist
serotonin 5-H T2 A receptor antagonist |
| gptkbp:appointed_by |
injection
oral tablet |
| gptkbp:approves |
gptkb:legislation
gptkb:2006 gptkb:Australia gptkb:FDA gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:brand |
gptkb:Invega_Sustenna
gptkb:Invega_Trinza gptkb:Invega |
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to paliperidone |
| gptkbp:developed_by |
gptkb:Johnson_&_Johnson
|
| gptkbp:duration |
short-term
long-term |
| gptkbp:excretion |
urine
|
| gptkbp:form |
oral tablet
injectable solution |
| gptkbp:formulation |
extended-release tablet
sustained-release injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Paliperidone
|
| gptkbp:ingredients |
C23 H27 Cl N4 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P2 D6 inhibitors |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
treatment of schizoaffective disorder
treatment of schizophrenia |
| gptkbp:lifespan |
23 hours
|
| gptkbp:manager |
intramuscular injection
oral administration |
| gptkbp:marketed_as |
gptkb:Invega_Sustenna
gptkb:Invega_Trinza gptkb:Invega |
| gptkbp:metabolism |
liver
|
| gptkbp:population |
adults
adolescents |
| gptkbp:related_to |
gptkb:risperidone
|
| gptkbp:research_focus |
long-term effects
schizoaffective disorder treatment schizophrenia treatment |
| gptkbp:side_effect |
drowsiness
weight gain increased cholesterol hyperglycemia extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia prolactin elevation |
| gptkbp:type_of |
144598-75-4
|